AI-081 is a PD-1 and VEGF bispecific antibody with best-in-class potential for the treatment of advanced solid tumors. Combining two proprietary and clinical-stage high-affinity anti-PD1 (AI-025 ...

Patients with anti–PD-1–resistant melanoma (MEL) have no well-defined standard of care. BO-112 is a synthetic, double-stranded RNA (poly I:C) nanoplexed with polyethylenimine that when administered ...

BioVie Inc. presented its SUNRISE-PD trial's patient-centric design at the ATMRD Congress, enhancing access for Parkinson's patients.

3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert Bourla, that landed in Pfizer’s cancer ...

2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from the Phase 1 PoC Clinical Study in ...

Applying this framework, the findings indicated that increasing Cu, Ag, and Al content significantly boosts activity for CO and C 2 formation, whereas Au, Pd, and Pt exhibit inhibitory effects.

The open-label, randomized, Phase 2 study will enroll approximately 50 patients with metastatic NSCLC whose tumors express PD-L1 and who have not previously received immune checkpoint inhibitors ...

Pfizer has linked its PD-1 inhibitor to a 32% reduction in the risk of disease-related events in a phase 3 bladder cancer trial. But the study fell short of a clean sweep of positive outcomes ...

Amneal shares data showing Crexont improves sleep and motor symptoms in Parkinson's patients, with Phase 4 trial underway for further evaluation.

Determination of Site Occupancy in the M–Pd–Zn (M = Cu, Ag, and Au) γ-Brass Phase by CALculation of PHAse Diagrams Modeling and Rietveld Refinement ...